SCHEMBL11900549

SCHEMBL11900549

CC(C)(C)OC(=O)N1CC(n2c(CCNC(=O)OCc3ccccc3)nc3ccc(F)cc32)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.45
BACE2 Q9Y5Z0 2/20 0.45
GNRHR P30968 1/20 0.43
ABCB1 P08183 1/20 0.41
MAPT P10636 1/20 0.40
P2RX7 Q99572 1/20 0.40
BRD4 O60885 2/20 0.40
RORC P51449 2/20 0.39
TNF P01375 1/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
NOD2 Q9HC29 1/20 0.38
NOD1 Q9Y239 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
SLC2A1 P11166 1/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12472635 0.89 HTT (0.40) GNRHRBRD4KEAP1NFE2L2CCNT1
SCHEMBL11900545 0.83 BACE1 (0.45) BACE1BACE2P2RX7RORCTNF
SCHEMBL11901466 0.83 ITGB3 (0.46) ABCB1MAPTBRD4KEAP1NFE2L2
SCHEMBL11901528 0.82 NOD2 (0.48) MAPTBRD4RORCKEAP1NFE2L2
SCHEMBL12472857 0.74 BRD4 (0.38) BACE1BACE2BRD4TNFCCNT1
SCHEMBL4938133 0.74 OPRM1 (0.49) MAPTRORCKEAP1NFE2L2
SCHEMBL21457809 0.74 ABCB1 (0.41) ABCB1MAPTP2RX7RORCKEAP1
SCHEMBL29576985 0.74 ABCB1 (0.41) ABCB1MAPTP2RX7RORCKEAP1
SCHEMBL29707414 0.73 ABCB1 (0.48) ABCB1MAPTKEAP1NFE2L2ITGB3
SCHEMBL21248918 0.73 ABCB1 (0.53) ABCB1MAPTKEAP1NFE2L2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 BACE1 371/4885BACE2 890/4885GNRHR 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.